{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:12:11Z","timestamp":1780315931224,"version":"3.54.1"},"reference-count":86,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T00:00:00Z","timestamp":1479168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1002\/hep.28848","type":"journal-article","created":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T09:02:17Z","timestamp":1474275737000},"page":"341-349","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["\u201cHep C, where art thou\u201d"],"prefix":"10.1097","volume":"65","author":[{"given":"Hugo Ram\u00f3n","family":"Rosen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-34-20241017","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/hep.27377","article-title":"Hepatitis C virus: the 25\u2010year journey from discovery to cure","volume":"60","author":"Ward","year":"2014","journal-title":"Hepatology"},{"key":"R2-34-20241017","first-page":"1416","article-title":"Hepatitis C recurrence after liver transplantation: is there cause for concern?","volume":"92","author":"Sorrell","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"R3-34-20241017","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1172\/JCI118842","article-title":"Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti\u2010viral cell\u2010mediated immune response","volume":"98","author":"Missale","year":"1996","journal-title":"J Clin Invest"},{"key":"R4-34-20241017","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/cid\/ciu077","article-title":"Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006\u20102010","volume":"58","author":"Mahajan","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R5-34-20241017","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/hep.28571","article-title":"Hepatitis C disease burden in the United States in the era of oral direct\u2010acting antivirals","volume":"64","author":"J","year":"2016","journal-title":"Hepatology"},{"key":"R6-34-20241017","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)\u2010infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"R7-34-20241017","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.bpg.2012.09.010","article-title":"Liver transplantation in the setting of chronic HCV","volume":"26","author":"Terrault","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R8-34-20241017","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/nm.3184","article-title":"Global control of hepatitis C: where challenge meets opportunity","volume":"19","author":"Thomas","year":"2013","journal-title":"Nat Med"},{"key":"R9-34-20241017","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLDIDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"R10-34-20241017","doi-asserted-by":"crossref","first-page":"407","DOI":"10.7326\/M14-1152","article-title":"Cost\u2010effectiveness of novel regimens for the treatment of hepatitis C virus","volume":"162","author":"Najafzadeh","year":"2015","journal-title":"Ann Intern Med"},{"key":"R11-34-20241017","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all\u2010cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"R12-34-20241017","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1586\/17474124.2015.1001366","article-title":"Achieving sustained virological response: what's the impact on further hepatitis C virus\u2010related disease?","volume":"9","author":"van der Meer","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"R13-34-20241017","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/hep.27766","article-title":"Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause\u2010specific outcomes","volume":"62","author":"Innes","year":"2015","journal-title":"Hepatology"},{"key":"R14-34-20241017","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/gutjnl-2014-308163","article-title":"Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection","volume":"64","author":"Hsu","year":"2015","journal-title":"Gut"},{"key":"R15-34-20241017","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.cgh.2011.03.004","article-title":"A sustained virologic response reduces risk of all\u2010cause mortality in patients with hepatitis C","volume":"9","author":"Backus","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R16-34-20241017","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1172\/JCI75938","article-title":"Endogenous intrahepatic IFNs and association with IFN\u2010free HCV treatment outcome","volume":"124","author":"Meissner","year":"2014","journal-title":"J Clin Invest"},{"key":"R17-34-20241017","doi-asserted-by":"crossref","first-page":"e1003330","DOI":"10.1371\/journal.ppat.1003330","article-title":"IL\u20101beta production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease","volume":"9","author":"Negash","year":"2013","journal-title":"PLoS Pathog"},{"key":"R18-34-20241017","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2014.10.040","article-title":"Hepatitis C virus infection induces autocrine interferon signaling by human liver endothelial cells and release of exosomes, which inhibits viral replication","volume":"148","author":"Giugliano","year":"2015","journal-title":"Gastroenterology"},{"key":"R19-34-20241017","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.coviro.2015.04.009","article-title":"Animal models for the study of HCV","volume":"13","author":"Vercauteren","year":"2015","journal-title":"Curr Opin Virol"},{"key":"R20-34-20241017","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nbt.2858","article-title":"Development and function of human innate immune cells in a humanized mouse model","volume":"32","author":"Rongvaux","year":"2014","journal-title":"Nat Biotechnol"},{"key":"R21-34-20241017","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"R22-34-20241017","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/apt.13343","article-title":"Improvement of liver function parameters in advanced HCV\u2010associated liver cirrhosis by IFN\u2010free antiviral therapies","volume":"42","author":"Deterding","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R23-34-20241017","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/lt.24324","article-title":"Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis","volume":"22","author":"Modi","year":"2016","journal-title":"Liver Transpl"},{"key":"R24-34-20241017","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27922","article-title":"Safety and efficacy of simeprevir\/sofosbuvir in hepatitis C\u2010infected patients with compensated and decompensated cirrhosis","volume":"62","author":"Saxena","year":"2015","journal-title":"Hepatology"},{"key":"R25-34-20241017","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open\u2010label, randomised, phase 2 trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R26-34-20241017","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitic C after viral eradication: a European study","volume":"65","author":"Belli","year":"2016","journal-title":"J Hepatol"},{"key":"R27-34-20241017","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/j.gastro.2016.03.036","article-title":"Effects of viral eradication in patients with hepatitis C Virus and cirrhosis differ with stage of portal hypertension","volume":"151","author":"Di Marco","year":"2016","journal-title":"Gastroenterology"},{"key":"R28-34-20241017","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon\u2010free therapies ameliorates HCV\u2010induced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J Hepatol"},{"key":"R29-34-20241017","first-page":"6963","article-title":"Favorable prognosis in patients with sustained virological response to antiviral therapy, including interferon, for chronic hepatitis C before hepatic resection for hepatocellular carcinoma","volume":"35","author":"Shirabe","year":"2015","journal-title":"Anticancer Res"},{"key":"R30-34-20241017","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J Hepatol"},{"key":"R31-34-20241017","doi-asserted-by":"crossref","first-page":"20310","DOI":"10.1038\/srep20310","article-title":"Global prevalence of pre\u2010existing HCV variants resistant to direct\u2010acting antiviral agents (DAAs): mining the GenBank HCV genome data","volume":"6","author":"Chen","year":"2016","journal-title":"Sci Rep"},{"key":"R32-34-20241017","first-page":"1688","article-title":"Sofosbuvir and velpatasvir for patients with HCV infection","volume":"374","author":"Feld","year":"2016","journal-title":"N Engl J Med"},{"key":"R33-34-20241017","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nbt.3179","article-title":"Clearance of persistent hepatitis C virus infection in humanized mice using a claudin\u20101\u2010targeting monoclonal antibody","volume":"33","author":"Mailly","year":"2015","journal-title":"Nat Biotechnol"},{"key":"R34-34-20241017","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1086\/656213","article-title":"The beginning of a new era in understanding hepatitis C virus prevention","volume":"202","author":"Rich","year":"2010","journal-title":"J Infect Dis"},{"key":"R35-34-20241017","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1097\/QAD.0b013e3282ef7701","article-title":"Preventing hepatitis C virus infection in injection drug users: risk reduction is not enough","volume":"21","author":"Page\u2010Shafer","year":"2007","journal-title":"AIDS"},{"key":"R36-34-20241017","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1086\/656212","article-title":"Survival of hepatitis C virus in syringes: implication for transmission among injection drug users","volume":"202","author":"Paintsil","year":"2010","journal-title":"J Infect Dis"},{"key":"R37-34-20241017","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","article-title":"Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews","volume":"378","author":"Nelson","year":"2011","journal-title":"Lancet"},{"key":"R38-34-20241017","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/infdis\/jiq111","article-title":"Prevention of hepatitis C virus in injecting drug users: a narrow window of opportunity","volume":"203","author":"Grebely","year":"2011","journal-title":"J Infect Dis"},{"key":"R39-34-20241017","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/infdis\/jiq112","article-title":"Changes in blood\u2010borne infection risk among injection drug users","volume":"203","author":"Mehta","year":"2011","journal-title":"J Infect Dis"},{"key":"R40-34-20241017","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugpo.2013.07.001","article-title":"Interventions to prevent HIV and hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness","volume":"25","author":"MacArthur","year":"2014","journal-title":"Int J Drug Policy"},{"key":"R41-34-20241017","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1360-0443.2009.02888.x","article-title":"Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews","volume":"105","author":"Palmateer","year":"2010","journal-title":"Addiction"},{"key":"R42-34-20241017","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1477-7517-3-27","article-title":"A review of the evidence for the effectiveness of primary prevention interventions for hepatitis C among injecting drug users","volume":"3","author":"Wright","year":"2006","journal-title":"Harm Reduct J"},{"key":"R43-34-20241017","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/cid\/cis393","article-title":"Evolving epidemiology of hepatitis C virus in the United States","volume":"55","author":"Klevens","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R44-34-20241017","doi-asserted-by":"crossref","first-page":"e1002876","DOI":"10.1371\/journal.pcbi.1002876","article-title":"Integrating phylodynamics and epidemiology to estimate transmission diversity in viral epidemics","volume":"9","author":"Magiorkinis","year":"2013","journal-title":"PLoS Comput Biol"},{"key":"R45-34-20241017","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/hep.26539","article-title":"Treatment as prevention: the breaking of taboos is required in the fight against hepatitis C among people who inject drugs","volume":"58","author":"Bruggmann","year":"2013","journal-title":"Hepatology"},{"key":"R46-34-20241017","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1093\/cid\/cit306","article-title":"Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta\u2010analysis","volume":"57","author":"Aspinall","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R47-34-20241017","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/hep.28227","article-title":"Hepatitis C treatment as prevention of viral transmission and liver\u2010related morbidity in persons who inject drugs","volume":"63","author":"Cousien","year":"2016","journal-title":"Hepatology"},{"key":"R48-34-20241017","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMra1200391","article-title":"Disease eradication","volume":"368","author":"Hopkins","year":"2013","journal-title":"N Engl J Med"},{"key":"R49-34-20241017","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1046\/j.1360-0443.2002.00208.x","article-title":"The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users","volume":"97","author":"Kwiatkowski","year":"2002","journal-title":"Addiction"},{"key":"R50-34-20241017","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1037\/a0028632","article-title":"Therapeutic alliance and treatment outcome in the primary care behavioral health model","volume":"30","author":"Corso","year":"2012","journal-title":"Fam Syst Health"},{"key":"R51-34-20241017","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.26623","article-title":"Eradication of hepatitis C infection: the importance of targeting people who inject drugs","volume":"59","author":"Hellard","year":"2014","journal-title":"Hepatology"},{"key":"R52-34-20241017","doi-asserted-by":"crossref","first-page":"9249","DOI":"10.1128\/JVI.00409-07","article-title":"Upregulation of PD\u20101 expression on circulating and intrahepatic hepatitis C virus\u2010specific CD8+ T cells associated with reversible immune dysfunction","volume":"81","author":"Golden\u2010Mason","year":"2007","journal-title":"J Virol"},{"key":"R53-34-20241017","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1128\/JVI.02021-06","article-title":"Liver\u2010infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD\u20101 and low levels of CD127 expression","volume":"81","author":"Radziewicz","year":"2007","journal-title":"J Virol"},{"key":"R54-34-20241017","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.immuni.2016.04.022","article-title":"Costimulatory and coinhibitory receptor pathways in infectious disease","volume":"44","author":"Attanasio","year":"2016","journal-title":"Immunity"},{"key":"R55-34-20241017","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1172\/JCI43127","article-title":"Tim\u20103 expression on PD\u20101+ HCV\u2010specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte\u2010directed in vitro cytotoxicity","volume":"120","author":"McMahan","year":"2010","journal-title":"J Clin Invest"},{"key":"R56-34-20241017","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/jvh.12465","article-title":"Memory re\u2010differentiation and reduced lymphocyte activation in chronic HCV\u2010infected patients receiving direct\u2010acting antivirals","volume":"22","author":"Burchill","year":"2015","journal-title":"J Viral Hepat"},{"key":"R57-34-20241017","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jhep.2014.05.043","article-title":"Restoration of HCV\u2010specific CD8+ T cell function by interferon\u2010free therapy","volume":"61","author":"Martin","year":"2014","journal-title":"J Hepatol"},{"key":"R58-34-20241017","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4049\/jimmunol.1203161","article-title":"Cutting edge: Prolonged exposure to HIV reinforces a poised epigenetic program for PD\u20101 expression in virus\u2010specific CD8 T cells","volume":"191","author":"Youngblood","year":"2013","journal-title":"J Immunol"},{"key":"R60-34-20241017","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1172\/JCI67714","article-title":"Emerging concepts in immunity to hepatitis C virus infection","volume":"123","author":"Rosen","year":"2013","journal-title":"J Clin Invest"},{"key":"R61-34-20241017","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.chom.2008.08.003","article-title":"Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines","volume":"4","author":"Barnes","year":"2008","journal-title":"Cell Host Microbe"},{"key":"R62-34-20241017","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.3748\/wjg.v20.i29.9633","article-title":"Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy","volume":"20","author":"Ansaldi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R63-34-20241017","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1055\/s-0034-1371081","article-title":"Will there be a vaccine to prevent HCV infection?","volume":"34","author":"Honegger","year":"2014","journal-title":"Semin Liver Dis"},{"key":"R65-34-20241017","doi-asserted-by":"crossref","first-page":"7005","DOI":"10.1128\/JVI.00586-11","article-title":"Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step","volume":"85","author":"Sabo","year":"2011","journal-title":"J Virol"},{"key":"R66-34-20241017","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nm.3183","article-title":"Current progress in development of hepatitis C virus vaccines","volume":"19","author":"Liang","year":"2013","journal-title":"Nat Med"},{"key":"R67-34-20241017","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/nm1353","article-title":"A T\u2010cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees","volume":"12","author":"Folgori","year":"2006","journal-title":"Nat Med"},{"key":"R68-34-20241017","doi-asserted-by":"crossref","first-page":"115ra111","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus\u2010based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci Transl Med"},{"key":"R69-34-20241017","doi-asserted-by":"crossref","first-page":"261ra153","DOI":"10.1126\/scitranslmed.3009185","article-title":"A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV\u2010specific T cell memory","volume":"6","author":"Swadling","year":"2014","journal-title":"Sci Transl Med"},{"key":"R70-34-20241017","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1016\/j.vaccine.2012.02.070","article-title":"Sustained viral load reduction in treatment\u2010naive HCV genotype 1 infected patients after therapeutic peptide vaccination","volume":"30","author":"Klade","year":"2012","journal-title":"Vaccine"},{"key":"R71-34-20241017","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jhep.2010.05.007","article-title":"A phase I clinical trial of dendritic cell immunotherapy in HCV\u2010infected individuals","volume":"53","author":"Gowans","year":"2010","journal-title":"J Hepatol"},{"key":"R72-34-20241017","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/hep.28294","article-title":"Chronic hepatitis C viral infection subverts vaccine\u2010induced T\u2010cell immunity in humans","volume":"63","author":"Kelly","year":"2016","journal-title":"Hepatology"},{"key":"R73-34-20241017","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/hep.28309","article-title":"Persistent hepatitis C viral replication despite priming of functional CD8(+) T cells by combined therapy with a vaccine and a direct\u2010acting antiviral","volume":"63","author":"Callendret","year":"2016","journal-title":"Hepatology"},{"key":"R74-34-20241017","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1126\/science.1088774","article-title":"HCV persistence and immune evasion in the absence of memory T cell help","volume":"302","author":"Grakoui","year":"2003","journal-title":"Science"},{"key":"R75-34-20241017","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/hep.28388","article-title":"Vaccine\u2010induced hepatitis C virus\u2010specific CD8(+) T cells do not always help","volume":"63","author":"Wieland","year":"2016","journal-title":"Hepatology"},{"key":"R76-34-20241017","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1128\/JVI.01581-07","article-title":"Spontaneous recovery in acute human hepatitis C virus infection: functional T\u2010cell thresholds and relative importance of CD4 help","volume":"82","author":"Smyk\u2010Pearson","year":"2008","journal-title":"J Virol"},{"key":"R77-34-20241017","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2893.1999.00008.x","article-title":"Cellular immune response to the hepatitis C virus","volume":"6","author":"Rehermann","year":"1999","journal-title":"J Viral Hepat"},{"key":"R78-34-20241017","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1128\/JVI.02265-09","article-title":"Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection","volume":"84","author":"Liu","year":"2010","journal-title":"J Virol"},{"key":"R79-34-20241017","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2249.1997.508-ce1412.x","article-title":"Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up","volume":"110","author":"Christie","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"R80-34-20241017","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virus\u2010neutralizing antibodies and viral clearance in a single\u2010source outbreak of hepatitis C","volume":"104","author":"Pestka","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R81-34-20241017","doi-asserted-by":"crossref","first-page":"8217","DOI":"10.1128\/JVI.79.13.8217-8229.2005","article-title":"An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high\u2010density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies","volume":"79","author":"Bartosch","year":"2005","journal-title":"J Virol"},{"key":"R82-34-20241017","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0140-6736(94)91224-6","article-title":"Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children","volume":"343","author":"Lai","year":"1994","journal-title":"Lancet"},{"key":"R83-34-20241017","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/ajt.12083","article-title":"Human monoclonal antibody MBL\u2010HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study","volume":"13","author":"Chung","year":"2013","journal-title":"Am J Transplant"},{"key":"R84-34-20241017","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/646851","article-title":"Hepatitis C virus infection in healthcare workers: risk of exposure and infection","volume":"15","author":"Lanphear","year":"1994","journal-title":"Infect Control Hosp Epidemiol"},{"key":"R85-34-20241017","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1089-3261(05)70321-4","article-title":"The epidemiology of acute and chronic hepatitis C","volume":"1","author":"Alter","year":"1997","journal-title":"Clin Liver Dis"},{"key":"R86-34-20241017","first-page":"1","article-title":"S. Public Health Service . Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis.","volume":"50","year":"2001","journal-title":"MMWR Recomm Rep"},{"key":"R87-34-20241017","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1128\/CMR.16.3.546-568.2003","article-title":"Managing occupational risks for hepatitis C transmission in the health care setting","volume":"16","author":"Henderson","year":"2003","journal-title":"Clin Microbiol Rev"},{"key":"R88-34-20241017","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1073\/pnas.1203110110","article-title":"Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half\u2010life","volume":"110","author":"Guedj","year":"2013","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.28848","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.28848","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.28848","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201701000-00034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T22:41:28Z","timestamp":1729204888000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201701000-00034"}},"subtitle":["What are the remaining (fundable) questions in hepatitis C virus research?"],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.28848","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}